晚期非小细胞肺癌中ERCC1、β-tubulin3 及TOPOⅡ的表达与临床病理特征及铂类化疗疗效的关系

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (0 KB) HTML (46 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨ERCC1、β-tubulin 3及TOPOⅡ在晚期非小细胞肺癌（NSCLC）中的表达与临床病理特征及与铂类化疗疗效的关系。方法选取2012年1月～2013年6月在我院治疗的61例晚期NSCLC住院患者作为研究对象，采用免疫组化方法检测其组织中ERCC1、β-tubulin 3及TOPOⅡ的表达，患者均接受培美曲塞联合奈达铂方案化疗并定期评价疗效。结果ERCC1、β-tubulin 3的表达与患者的年龄、性别、临床分期及组织学类型均无关（P＞0.05）；TOPOⅡ的表达与患者的年龄、性别、临床分期无关（P＞0.05）；TOPOⅡ在腺癌中阳性表达8例（22.86%），鳞癌阳性表达14例（53.85%），鳞癌的表达高于腺癌，差异有统计学意义（P=0.017）。ERCC1、β-tubulin 3及TOPOⅡ的阳性表达分别为40.98%（25/61）、47.54%（29/61）及36.66%（22/61），阳性表达化疗有效率分别为16.00%（4/25）、48.28%（14/29）及63.64%（14/22），阴性表达化疗有效率分别为63.89%（23/36）、40.63%（13/32）及33.33%（13/39）。结论ERCCI及TOPOⅡ阳性可预测NSCLC对铂类化疗药物的疗效，且TOPOⅡ对不同组织学类型的晚期非小细胞肺癌疗效预测具有重要意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张春节
	姜维美
	韩磊
	孙咏梅

关键词 ：非小细胞肺癌, ERCC1, &beta, -tubulin 3, TOPOⅡ, 免疫组化

Abstract：ObjectiveTo explore the expressions of ERCC1,β-tubulin 3 and TOPOⅡin advanced non-small-cell lung cancer(NSCLC)and their correlations with clinical pathological features and efficacy of platinum based chemotherapy.Methods61 patients with NSCLC in our hospital from January 2012 to June 2013 were selected as the study subjects, mmunohistochemical method was used to detect the expression of tissue ERCC1 and β-tubulin 3 and TOPOⅡ,All the patientswere treated with Pemetrexed combined with Nedaplatin chemotherapy,and the efficacy was evaluated on a regular.ResultsThe express of ERCC1 and β-tubulin 3 was not related to the age,sex,clinical stage and histological type of the patient(P＞0.05).The expression of TOPOⅡwas not related to the age,sex,and clinical stage of the patients (P＞0.05).The positive expression of TOPOⅡin adenocarcinoma was 8 cases(22.86%),14 cases(53.85%)were positive in squamous cell carcinoma,and the positive expression of ERCC1,β-tubulin 3 and TOPOⅡ in squamous cell carcinoma was higher than that in adenocarcinoma,with significant difference(P=0.017).The positive expression of ERCC1, β-tubulin 3 and TOPOⅡwere 40.98%(25/61),47.54%(29/61)and 36.66%(22/61)respectively,the effective rate of positive expression of chemotherapy was 16.00%(4/25),48.28%(14/29)and 63.64%(14/22),the effective rate of negative expression of chemotherapy was 63.89%(23/36),40.63%(13/32)and 33.33%(13/39).ConclusionThe positive expression of ERCCI and TOPOⅡcan predict the efficacy of NSCLC in the treatment of platinum based chemotherapy drugs,and TOPOⅡhas important significance for the prognosis of advanced NSCLC with different histological types.

Key words： Non-small-cell lung cancer ERCC1 &beta tubulin 3 TOPOⅡ Immunohistochemistry

基金资助:江苏省连云港市卫生计生委科研项目（1319）

通讯作者: 孙咏梅（1967-），女，本科，主任医师，主要从事临床病理诊断工作

作者简介: 张春节（1985-），男，本科，主治医师，主要从事临床病理诊断工作

引用本文:

张春节;姜维美;韩磊;孙咏梅. 晚期非小细胞肺癌中ERCC1、β-tubulin3 及TOPOⅡ的表达与临床病理特征及铂类化疗疗效的关系[J]. 中国当代医药, 2016, 23(35): 7-10.
ZHANG Chun-jie;JIANG Wei-mei;HAN Lei;SUN Yong-mei. Expression of ERCC1,β-tubulin 3 and TOPOⅡin advanced non-smallcell lung cancer and their relationship with clinical pathological features and efficacy of platinum based chemotherapy. 中国当代医药, 2016, 23(35): 7-10.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2016/V23/I35/7

[12]	MiaoZH，DingJ.Transcriptionfactorc-Junactivationrepresses mdr-1 gene expression[J].Cancer Res，2003，63（15）：4527-4532.
[14]	秦超，姬明丽，翟红娟.Topo-Ⅱ蛋白在非小细胞肺癌中表达与耐药性的关系[J].中国误诊学杂志，2007，7（18）：4206-4208.
[2]	Mountain CF，Dresler CM.Regional lymph node classification for lung canner stagjng[J].Chest，1997，111（6）：1718-1723.
[3]	汤钊酋.现代肿瘤学[M].上海：上海医科大学出版社，2000：859-860，888-889.
[10]	郑少江，吴焕明，王伟.LRP，Topo-Ⅱ在非小细胞肺癌中的协同表达及其临床意义[J].中国组织化学与细胞化学杂志，2004，13（2）：180-184.
[11]	海峰，竺王玉，黄燕燕，等.Gelsolin、P-gp、TopoⅡ、GST-Π检测在非小细胞肺癌预后中的价值[J].中国中西医结合外科杂志，2012，18（1）：9-14.
[1]	Soo RA，WangLZ，Thaml S，et al.A multicentre randomised phaseⅡ study ofCarboplatin in combination with gemcitabine at standard rate or fixed dose rate in fusion in patients with advanced stage non-small-cell lung cancer[J]. Ann Oncol，2006，17（7）：1128-1133.
[4]	Zhang HL，Ruan L，Zheng LM，et al.Association between classⅢβ-tubulin expression and response to paclitaxel/vinorebinebased chemotherapy for non-small cell lung cancer：a meta-analysis[J].Lung Cancer，2012，77（1）：9-15.
[5]	Tsodikow OV，Ivanov D，Orelli B，et al.Structural basis for the recruitment of ERCC1-XPF to nuclecotide excision repair complexes by XPA[J].EMBO，2007，6（12）：4768-4776.
[6]	Roth JA，Carlson JJ.Prognostic role of ERCC1 in advanced non-small-cell lung cancer：a systematic review and metaanalysis[J].Clin Lung Cancer，2011，12（6）：393-401.
[7]	Reynolds C，Obasaju C，Schell MJ，et al.Randomized phase Ⅲ trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 portein levels for response prediction in non-small-cell lung cancer[J].J Clin Oncol，2009，27（34）：5808-5815.
[8]	Olaussen KA，Dunant A，Fouret P，et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med，2006，355（10）：983-991.
[9]	Rybárová S，Muri J，Hodorová I，et al.Importance of expression of DNA repair proteins in non-small-cell lung cancer [J].Klin Onkol，2012，25（5）：370-374.
[13]	Mistry P，Stewart AJ，Dangerfield W，et al.Invitro and invivo characterization of XR11576，anovel，orally active，dual inhibitor of topoisomeraseⅠandⅡ[J].Anti Cancer Drugs，2002，13（1）：15-28.
[15]	Seve P，Dumontet C.Is classⅢ beta-tubulin a predictive factor in patients receiving tubulin-binding agents[J]. Lancet Oncol，2008，9（2）：168-175.
[16]	Seve P，Mackey J，Isaac S，et al.ClassⅢ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel[J].Mol Cancer Ther，2005，4（12）：2001-2007.
[17]	Kaira K，Takahashi T，Murakami H，et al.The role of βⅢ-tubulin in non-small cell lung cancer patients treated by taxanebased chemotherapy[J].Int J Clin Oncol，2013，18（3）：371-379.
[18]	Joerger M，Dejong D，Burylo A，et al.Tubulin，BRCA1，ERCC1，Abraxas，RAP80 mRNA expression，p53/p21 immunohistochemistry and clinical outcome in patients with advanced non-small cell lung cancer receiving first-line platinumgemcitabine chemotherapy[J].Lung Cancer，2011，74（2）：310-317.
[19]	Gan PP，Pasquier E，Kavallaris M.ClassⅢ beta-tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer[J].Cancer Res，2007，67（19）：9356-9363.
[20]	Huang CL，Kadota K，Liu D，et al.Expression of ERCCl and classⅢβ-tubulin is associated with the survival of resected stageⅢ non-small cell lung cancer patients treated with induction che moradiothempy using carboplatin-taxane[J].Exp Ther Med，2010，1（3）：445-451.